UPDATE 2-GlaxoSmithKline's new boss streamlines R&D, ditches non-core drugs
July 26, 2017 at 08:22 AM EDT
* Q2 adjusted EPS 27.2p vs consensus forecast 26.2p (Adds further details and quotes from CEO and analysts)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.